Serrapeptase

What is Serrapeptase?

Serrapeptase is a serine protease enzyme produced by the enterobacterium Serratia marcescens, first isolated from silkworm intestines where it dissolves the silkworm's cocoon. It is not found in food but is manufactured through microbial fermentation and formulated as an enteric-coated supplement to survive stomach acid. It has been used clinically in Japan and parts of Europe for decades as an anti-inflammatory and mucolytic agent, though regulatory approval status varies significantly by country.

How does Serrapeptase work?

Serrapeptase works primarily by hydrolyzing bradykinin, fibrin, and other inflammatory peptides at sites of tissue damage, which reduces localized swelling and pain signaling. It also degrades viscous mucoproteins in mucus secretions, making them thinner and easier to clear from respiratory passages. Some research suggests it may inhibit biofilm formation and enhance antibiotic penetration into infected tissue, though this evidence is largely from in vitro and animal models.

What forms does Serrapeptase come in?

Serrapeptase must be taken as an enteric-coated or delayed-release formulation to ensure intestinal absorption intact. Standard commercial forms include enteric-coated tablets and capsules ranging from 10 mg (approximately 20,000 SU) to 60 mg (approximately 120,000 SU). Powder or non-coated formulations are unlikely to deliver active enzyme systemically.

Where it comes from:

Serrapeptase was first identified in the 1950s by Japanese researchers studying silkworm biology. It was developed as a pharmaceutical in Japan and Germany through the 1960s–1980s and has been registered as a drug in several Asian and European countries. It remains a prescription anti-inflammatory in Japan and is widely sold as a supplement in the UK, US, and India.

What does Serrapeptase help with?

• Post-surgical and post-traumatic swelling: Serrapeptase reduces edema by breaking down inflammatory exudate proteins, particularly fibrin and bradykinin, at the injury site. A double-blind RCT by Tachibana et al. (1984, Pharmatherapeutica) in patients following orthopedic surgery found serrapeptase significantly reduced swelling and pain versus placebo. A subsequent multi-center RCT by Esch et al. (1989, Fortschritte der Medizin) in post-operative dental surgery patients similarly demonstrated faster reduction in cheek swelling with serrapeptase compared to placebo, though effect sizes were modest.
• Sinusitis and chronic rhinosinusitis: Serrapeptase thins viscous nasal and sinus mucus by cleaving mucoproteins, facilitating drainage and reducing sinus pressure. A double-blind RCT by Majima et al. (1988, Otolaryngology) involving patients with chronic sinusitis found serrapeptase significantly reduced secretion viscosity and patient-reported symptoms compared to placebo over a 4-week treatment period. Its mucolytic action is complementary to antibiotic therapy and has been studied in combination contexts.
• Musculoskeletal pain and inflammation: By degrading inflammatory mediators including bradykinin and histamine precursors at pain receptor sites, serrapeptase can attenuate pain signals in soft tissue injuries and arthritis. Clinical evidence is limited but includes small RCTs in lateral epicondylitis and ankle sprains showing reduced pain scores versus placebo. Evidence in this area is less robust than in post-surgical contexts and would benefit from larger confirmatory trials.
• Carpal tunnel syndrome: Serrapeptase may reduce the peritendinous fibrin and inflammatory exudate that contributes to median nerve compression in carpal tunnel syndrome. A small RCT by Panagariya and Sharma (1999, Journal of the Association of Physicians of India) in 20 patients found statistically significant improvements in pain and grip strength with serrapeptase versus placebo, though the small sample size limits generalizability.
• Breast engorgement: Serrapeptase has been studied for fibrocystic breast conditions and postpartum breast engorgement, where its proteolytic action on inflammatory exudate and fibrous tissue may provide relief. A double-blind RCT by Kee et al. (1989, Singapore Medical Journal) found serrapeptase significantly superior to placebo in reducing pain, swelling, and induration in nursing mothers with breast engorgement, representing one of the better-controlled trials in this indication.

What can Serrapeptase help prevent?

• Delayed wound healing complications (by reducing fibrin accumulation at surgical sites, supported by post-surgical trial data)
• Mucus impaction and sinopulmonary obstruction in chronic rhinosinusitis (supported by mucolytic clinical trials)

Which foods are rich in Serrapeptase?

Serrapeptase is a microbially-derived enzyme supplement with no direct food source — dietary proteins do not supply this specific protease. However, a diet rich in other proteolytic-enzyme-containing foods supports a broadly similar anti-inflammatory and digestive pathway: fresh pineapple (bromelain), raw papaya (papain), fresh ginger (zingibain), kefir and fermented dairy (microbial proteases), and fermented soy products such as natto (nattokinase) are all natural sources of proteolytic enzymes with overlapping anti-inflammatory and fibrinolytic mechanisms. Minimizing ultra-processed foods and refined sugars supports a lower systemic inflammatory baseline, complementing serrapeptase therapy. Foods rich in zinc (pumpkin seeds, legumes, shellfish) support endogenous protease activity, which aligns with serrapeptase's zinc-dependent mechanism.

What are the side effects of Serrapeptase?

• Nausea and mild GI upset (most common, particularly with non-enteric-coated preparations)
• Skin rash or urticaria (hypersensitivity reactions)
• Muscle aches and joint pain (reported in some users at higher doses)
• Appetite disturbance
• Rare: pneumonitis or pulmonary eosinophilia (case reports, primarily from Japan)
• Rare: blood-tinged sputum (due to mucolytic activity in respiratory secretions)

Good to know:

Serrapeptase is generally well tolerated in clinical trials at standard doses (10,000–120,000 SU/day) for periods up to 4 weeks. Most adverse events are mild and transient. Rare but serious adverse events including serrapeptase-induced pneumonitis and pulmonary infiltrates have been reported in case series from Japan, warranting discontinuation if respiratory symptoms develop.

How much Serrapeptase should you take?

• Recommended daily: 10 mg to 60 mg (approximately 20,000–120,000 SU) per day in divided doses; most clinical trials used 10–30 mg/day (20,000–60,000 SU/day) for anti-inflammatory indications. Higher doses (60,000–120,000 SU/day) are used for mucolytic purposes in some protocols.
• Best time of day: Between meals — typically 30–60 minutes before meals or at least 2 hours after eating to ensure enzymatic activity is not consumed by food digestion.
• With or without food: Must be taken away from food. Enteric-coated tablets/capsules should be swallowed whole and not crushed or chewed.
• Time to effect: Swelling and pain relief: 3–10 days; mucolytic benefit: 1–4 weeks; some studies report benefits beginning within 3 days of initiation.
• How long to take it: Clinical trials typically ran 1–4 weeks for acute indications. For chronic conditions, use beyond 4 weeks should be supervised by a healthcare provider. No standard cycling protocol is established; periodic reassessment every 4 weeks is advisable.